The Boards of Kowa Research Europe Ltd. (KRE) and Kowa Pharmaceutical Europe C. Ltd. (KPE) are pleased to announce the appointment of Dr Ralph Zaat as the President of the Companies, with effect from the 1st February 2016.

Dr Zaat has previously enjoyed a successful career in the Pharmaceutical Industry working in a number of senior positions with Novartis Pharma AG, Merck Serono International S.A. and more recently with the Portuguese family owned business, Bial Pharma. He has previous working experience in European, Asia Pacific and developing market businesses within both commercial and senior management roles.

“We are delighted to welcome him to his new position in Kowa and anticipate a fruitful and successful working future together, as part of the Kowa family of businesses.”

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.